ArticlePediatric dermatology
Prescribing Patterns in Pediatric Hidradenitis Suppurativa.
Article in Pediatric dermatology. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
Hidradenitis suppurativa (HS) is an inflammatory skin condition increasingly diagnosed in pediatric populations; however, data on treatment practices in this group remains limited. In this retrospective study of 163 patients diagnosed with HS ≤ 18 years of age, we found that treatment patterns varied significantly by disease severity. As compared to patients with Hurley stage I (HSI) disease, those with Hurley stage III (HSIII) were more likely to receive: biologics (11.8% versus 58.3%, p < 0.001), chlorhexidine (47.1% versus 75.0%, p = 0.009), intralesional steroid injections (20.0% versus 58.3%, p < 0.001), metformin (3.53% versus 22.2%, p = 0.006), oral steroids (0%, versus 19.4%, p < 0.001), and spironolactone (10.6% versus 38.9%, p = 0.001). Higher Hurley stage was also associated with higher odds of receiving pain management prescriptions (NSAIDs [10.6% HSI versus 26.2% Hurley stage II (HSII) versus 52.8% HSIII; p < 0.001] and opioids [3.6% HSI versus 9.3% HSII versus 31.0% HSIII; p < 0.001]).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.